Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

This study is tracking real-world outcomes for Chinese patients with a specific type of non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who are being treated with sotorasib (a targeted drug). Researchers want to understand how well the drug works in everyday clinical practice. **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic non-small cell lung cancer with a confirmed KRAS G12C mutation - You have received at least one prior cancer treatment - You have received at least one dose of sotorasib - You are of Chinese ethnicity **You may NOT be eligible if...** - You are documented as being of non-Chinese ethnicity Talk to your doctor to see if this trial is right for you.